Bio-Techne Corporation logo

Bio-Techne Corporation

TECH | NASDAQ
Chart Builder DCF Calculator
$72.68
+$0.02 (+0.03%)
Nov 2, 2026, 1:15 PM ET · Market open

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Key Executives

Name Position
Kim Kelderman Chief Executive Officer, President & Director
Gary J. Latham Vice President & Chief Technology Officer
James T. Hippel Executive Vice President of Finance & Chief Financial Officer
Cheryl Bethune Senior Vice President & Chief Human Resources Officer
David Clair Vice President of Investor Relations
Gerry Andros Vice President of Sales and Marketing
Luca Cicchetti Managing Director
Martin Wirtz Senior Vice President of Strategy & Corporate Development
Shane Bohnen Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer
Steve Crouse President of Diagnostics & Spatial Biology Segment
William A. Geist President of Protein Sciences Segment

Latest SEC Filings

Date Type Title
Sep 30, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 23, 2026 8-K Current Report
Sep 14, 2026 DEFA14A Filing
Sep 14, 2026 8-K Current Report
Sep 09, 2026 DEFA14A Filing
Sep 02, 2026 DEFA14A Filing
Aug 25, 2026 DEFA14A Filing
Aug 24, 2026 10-K Annual Report
Aug 20, 2026 DEFM14A Filing
View All SEC Filings ➞
Bio-Techne Corporation
Bio-Techne Corporation logo
Country United States
IPO Date Feb 9, 1989
Industry Biotechnology
Sector Healthcare
Employees 3,000
CEO Kim Kelderman

Contact Details

614 McKinley Place N.E. Minneapolis, Minnesota 55413 United States

Stock Details

Ticker Symbol TECH
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000842023
CUSIP Number 09073M104
ISIN Number US09073M1045
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.